Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report
Cytokine release syndrome (CRS) is a well-described immune-related adverse event following chimeric antigen receptor T-cell therapy, but has rarely been reported following anti-programmed death ligand-1 therapy. We report the case of a 55-year-old man with metastatic lung adenocarcinoma who presente...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-07-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/9/7/e002855.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846173167187394560 |
|---|---|
| author | Chul Kim Paul Sackstein Jacob Zaemes |
| author_facet | Chul Kim Paul Sackstein Jacob Zaemes |
| author_sort | Chul Kim |
| collection | DOAJ |
| description | Cytokine release syndrome (CRS) is a well-described immune-related adverse event following chimeric antigen receptor T-cell therapy, but has rarely been reported following anti-programmed death ligand-1 therapy. We report the case of a 55-year-old man with metastatic lung adenocarcinoma who presented with fever, chills and hypotension. Initial labs were notable for highly elevated serum ferritin levels and mildly elevated triglyceride levels. He was ultimately diagnosed with pembrolizumab-induced CRS complicated by multiorgan failure. The patient was treated with steroids and tocilizumab with normalization of inflammatory markers and resolution of renal failure. This case not only highlights the importance of considering CRS in patients who have developed multiorgan failure after immune checkpoint inhibitor therapy, but also demonstrates clinical similarities between CRS and other hyperinflammatory states such as hemophagocytic lymphohistiocytosis. |
| format | Article |
| id | doaj-art-5fb6b65bcb1145da8e5ec2dbe9e18865 |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2021-07-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-5fb6b65bcb1145da8e5ec2dbe9e188652024-11-08T14:40:10ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262021-07-019710.1136/jitc-2021-002855Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case reportChul Kim0Paul Sackstein1Jacob Zaemes22 Division of Hematology and Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA1 Internal Medicine, MedStar Georgetown University Hospital, Washington, District of Columbia, USALombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, District of Columbia, USACytokine release syndrome (CRS) is a well-described immune-related adverse event following chimeric antigen receptor T-cell therapy, but has rarely been reported following anti-programmed death ligand-1 therapy. We report the case of a 55-year-old man with metastatic lung adenocarcinoma who presented with fever, chills and hypotension. Initial labs were notable for highly elevated serum ferritin levels and mildly elevated triglyceride levels. He was ultimately diagnosed with pembrolizumab-induced CRS complicated by multiorgan failure. The patient was treated with steroids and tocilizumab with normalization of inflammatory markers and resolution of renal failure. This case not only highlights the importance of considering CRS in patients who have developed multiorgan failure after immune checkpoint inhibitor therapy, but also demonstrates clinical similarities between CRS and other hyperinflammatory states such as hemophagocytic lymphohistiocytosis.https://jitc.bmj.com/content/9/7/e002855.full |
| spellingShingle | Chul Kim Paul Sackstein Jacob Zaemes Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report Journal for ImmunoTherapy of Cancer |
| title | Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report |
| title_full | Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report |
| title_fullStr | Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report |
| title_full_unstemmed | Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report |
| title_short | Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report |
| title_sort | pembrolizumab induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma a case report |
| url | https://jitc.bmj.com/content/9/7/e002855.full |
| work_keys_str_mv | AT chulkim pembrolizumabinducedcytokinereleasesyndromeinapatientwithmetastaticlungadenocarcinomaacasereport AT paulsackstein pembrolizumabinducedcytokinereleasesyndromeinapatientwithmetastaticlungadenocarcinomaacasereport AT jacobzaemes pembrolizumabinducedcytokinereleasesyndromeinapatientwithmetastaticlungadenocarcinomaacasereport |